Clinical Trial Update: Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating N91115 in cystic fibrosis patients with homozygous F508del-CFTR mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• N91115

Snippet

Sponsor: Nivalis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED